Comparison of the clinical utility of two-dimensional ultrasonography and elastosonography in evaluating endometrial thickness in breast cancer patients

The purpose of this study is to assess the diagnostic performance of elastosonography in comparison to two-dimensional ultrasonography for evaluating endometrial thickness in breast cancer patients receiving tamoxifen therapy. A total of 98 women who had received tamoxifen therapy for breast cancer were enrolled in this study. A retrospective chart review was conducted to collect relevant medical, obstetrical, and gynecological information, as well as detailed histories of breast cancer. Clinical imaging data were also obtained, and endometrial thickness was measured using both conventional two-dimensional ultrasonography and elastosonography techniques. The differences between the two methods were quantified by calculating the delta value, and potential influencing factors were analysed using statistical methods. All patient data were de-identified prior to analysis in order to maintain confidentiality and protect patient privacy. Our study found a statistically significant difference in mean endometrial thickness measurements between two-dimensional ultrasonography (5.81mm, SD = 3.09) and elastosonography (3.07mm, SD = 1.62) in breast cancer patients on tamoxifen therapy. Logistic regression analysis revealed that patient age and medication duration of tamoxifen were significant factors influencing the degree of difference between these measurements. Elastosonography may offer a more precise and sensitive imaging modality for monitoring endometrial thickness in the patient with breast cancer. Clinicians should consider these findings when evaluating and managing potential endometrial changes associated with tamoxifen therapy.